Tailoring vaccine protocols to benefit the patient and practiceMay 22, 2019More and more pet owners are starting to question veterinarians and their staff about the need for vaccinating their pets due to misinformation on the internet, as well as sensationalized stories about pets who may, or may not, have experienced a vaccine reaction. Those in opposition of vaccines are passionate about their views, while those in favor are equally vehement on the subject. Is one side right and the other wrong, or is there common ground to be found? Likely a little of both. Not all is yet known about the immune system, and there is still research that needs to be done. As such, recommendations offered today are based on current information, with the full knowledge they could change in the future. Not what they used to be Vaccines were developed to help prevent infectious disease, which they do, and vaccine technology has advanced tremendously since the inception of vaccinology. Vaccine opponents often argue ingredients such as adjuvants (e.g. aluminum, mercury, formaldehyde, and foreign proteins) are reasons to not vaccinate, as they can be the cause of adverse advents. This was true in the past; however, many vaccines have been "purified" over the years through the removal of …
SPONSORED CONTENTStraight Talk with Clients is a Critical Piece of the Adverse Food Reaction "Puzzle"Managing dogs with adverse food reactions can be a puzzle for veterinarians and a wait-and-see game for clients. +
Is fear driving the anti-vaccine movement?May 22, 2019Vaccines are one of the most effective means for preventing disease ever developed and one of the great triumphs of scientific medicine. Widespread vaccination of children has dramatically reduced—and in some cases eliminated—infectious diseases that have plagued humanity for thousands of years. There is less research evidence for the impact of vaccination in companion animals, but there is ample reason to believe vaccines have been equally successful in dogs and cats.3–7 Any veterinarian old enough to remember the emergence of canine parvovirus (CPV) in the U.S. in the late 1970s, for example, would probably testify to the efficacy of vaccination in reducing the incidence of this disease.5–7 There also is compelling evidence showing the reduction of both canine and human rabies cases due to vaccination programs aimed at dogs.8–12 And similar to smallpox, the veterinary disease rinderpest was eradicated largely due to the use of an effective vaccine.13 Vaccines and autism Despite the evident success of vaccination in reducing morbidity and mortality, there has always been controversy about the practice.14 The introduction of widespread vaccination in children was initially met with resistance and legal challenges. There was fear about the safety of vaccines, as well as resistance rooted in …
2019 World Veterinary Day highlights the value of vaccinesMarch 12, 2019Vaccines are critical to animal health, which is why this year World Veterinary Day (WVD) is focusing on the value of vaccination. Created by the World Veterinary Association (WVA) in 2000, WVD reminds pet owners of the importance of animal care, and how veterinarians and their teams can help. According to the WVA, vaccines are an essential tool for preventive veterinary medicine, promotion of animal health and welfare, and reducing the risk of human exposure to many zoonotic pathogens. Vaccination programs can reduce the need for antimicrobials, and in turn, decreases the risk of emergent antimicrobial resistance. According to WVA and HealthforAnimals, it is vital for the global veterinary profession to educate the public, particularly animal owners and producers, about the benefits of vaccination for animal, human, and public health. This year, WVD takes place on April 27.
Boehringer Ingelheim announces $80M expansion investmentDecember 5, 2017Boehringer Ingelheim announced it will invest more than $80 million to expand its existing facilities in Athens, Ga., and St. Joseph, Mo., to accommodate increased production of animal vaccines. The company's facility in Athens, Ga., will grow from its current footprint of approximately 350,000 square feet to 400,000 square feet, and will nearly double its filling capacity for companion animal and avian vaccines. Construction is slated to begin in the fourth quarter of 2017 and will continue through 2019, with commercial production anticipated to begin in the second half of 2019. The facility employs approximately 400; research and development operations also are based there. The company expects to add 50 positions over the next three years to support the expansion. Construction at the company's facility in St. Joseph, Mo., also will begin in the fourth quarter 2017 on a 13,000-square-foot expansion to accommodate increased production of livestock animal vaccines sold in the U.S. and globally. The manufacturing operation is part of a 700,000-square-foot total campus in St. Joseph, which also includes a warehouse, research and development, and other support functions. Twenty additional jobs will be created over the next few years to support the increased …
